Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.
about
Pathogenesis of human immunodeficiency virus infectionEffects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoproteinHuman immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events.Membrane skeleton restraint of surface shape change during fusion of erythrocyte membranes: evidence from use of osmotic and dielectrophoretic microforces as probesV3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical TriaAdaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.Virus receptors: implications for pathogenesis and the design of antiviral agents.Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions.Replication of macrophage-tropic and T-cell-tropic strains of human immunodeficiency virus type 1 is augmented by macrophage-endothelial cell contact.Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease courses.A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3.Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hosts.Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.gp120-independent fusion mediated by the human immunodeficiency virus type 1 gp41 envelope glycoprotein: a reassessment.Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope proteinSpontaneous substitutions in the vicinity of the V3 analog affect cell tropism and pathogenicity of simian immunodeficiency virus.The "V3" domain is a determinant of simian immunodeficiency virus cell tropism.Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regionsEvidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability.The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein.Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.Simian immunodeficiency virus variants with differential T-cell and macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry.A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody.Changes in the cytopathic effects of human immunodeficiency virus type 1 associated with a single amino acid alteration in the ectodomain of the gp41 transmembrane glycoprotein.Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope.Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites.Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region.Fitness disadvantage of transitional intermediates contributes to dynamic change in the infecting-virus population during coreceptor switch in R5 simian/human immunodeficiency virus-infected macaques.Surface shape change during fusion of erythrocyte membranes is sensitive to membrane skeleton agents.
P2860
Q24634681-E4FA486D-FDD4-4F7E-BB3E-ECA52D449326Q28646850-E0C1E70B-74B4-48FA-A2A0-F1233BAD4844Q33720162-414DE9F9-2DEF-420B-B290-AD86D707CBE6Q33936268-D60927A7-43BC-49B5-8D9D-5C0CEE3B62B1Q34047803-1279B26F-A1C1-4CD2-8EDF-9E846AE124EFQ34171212-DF89761E-30DB-4CF9-88E5-0D0C773D1553Q34610959-6E567CCC-A9F9-4134-B909-432F24043C10Q35366667-A5B711DF-2F5A-4A41-8D49-5FE6A33B51A9Q35835261-6DAB26A6-EF92-4D29-840E-391DD8470A8FQ35837334-BB6BA5CD-F105-41EF-8E54-2FB5BB9766E5Q35861228-D58B95F8-B7B7-44DE-B901-B1AEC8C21C0CQ35877501-C7851423-B30B-4DB9-BD3E-2E02E52D07D2Q35994354-57D8FBD4-2A0F-4A7D-B064-C243C87C7A54Q36628256-EAEAC98D-83E1-4E63-8232-66DD5098E37DQ36630580-7CEAC414-F100-4CF5-8DF9-E676C6ED4CD8Q36632605-01D91D0B-BB92-4D37-87DB-1FED853B3E43Q36632673-1BDB0F5D-76EC-4C59-9381-FDD2D68940A7Q36634149-7263A807-C523-4404-9A58-B98E035A4548Q36634341-B862E845-96AB-4564-B85B-5509BC1D1B61Q36649240-965015DA-61ED-4B8E-A00F-1F31EC1F2BD1Q36649958-C2784368-F72E-4139-B56D-437A37DB8FC2Q36650881-08D9A459-4963-4170-BBCB-1133A1872E84Q36652422-2B70886C-B966-450E-8762-9DC768B5C97FQ36669879-AAD0A2C9-8F69-4D9F-A5CA-78C4AD21AE65Q36676729-4B9E0BC4-C5C4-4A32-9B60-99F3C3638F0AQ39143639-9D965EC1-88A2-42DD-A8D7-252E097570ECQ39880808-4CDC25B7-274D-49C4-A919-A916A318C8F7Q40038304-B7A5A3C6-62D0-421F-A2AB-60E48E089A90Q40038327-3CA961B6-1F89-461D-92B8-9E93E9B6ED5BQ40046473-4EADAB08-C8B0-44E3-8F70-31F01B9D9754Q40047212-536D78E5-1860-44CB-9ADA-8A45C3AADB34Q40060900-0D17E5EE-16BA-4DAB-A78B-0271EDCF8E82Q40061779-9CC5F2C0-D0AB-4033-B4F1-561CAD08F24BQ41230660-468F2A42-7556-47FC-8F21-34BF5AD14F10Q41791335-1E4831D1-75DD-45F2-A1D7-C151095A23D6
P2860
Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Mutations in the principal neu ...... kinetics, and neutralization.
@en
type
label
Mutations in the principal neu ...... kinetics, and neutralization.
@en
prefLabel
Mutations in the principal neu ...... kinetics, and neutralization.
@en
P2093
P2860
P1433
P1476
Mutations in the principal neu ...... kinetics, and neutralization.
@en
P2093
B A Fuller
M B Nelson
M L Hammarskjöld
P D Rennert
R J Grimaila
S D Putney
P2860
P304
P407
P577
1992-04-01T00:00:00Z